Cip2a

Uses your system voice; voice and rate in settings.

Q21129704Snapshot

≈ 2 min read

Names in other languages

  • DeutschC330027C09Rik
  • EspañolC330027C09Rik
  • FrançaisC330027C09Rik
  • NederlandsC330027C09Rik
  • PortuguêsC330027C09Rik
  • srnC330027C09Rik
  • SvenskaC330027C09Rik
  • EnglishCip2a

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Protein CIP2A also known as cancerous inhibitor of PP2A (CIP2A) is a protein that in humans is encoded by the KIAA1524 gene. CIP2A is a regulatory protein involved in the inhibition of the serine-threonine phosphatase activity of Protein phosphatase 2A (PP2A). PP2A is a trimeric enzyme composed of a catalytic C-subunit, a scaffolding A-subunit, and various regulatory B-subunits, which collectively dephosphorylate a vast majority of cellular serine/threonine phosphorylated proteins, including many involved in cancer progression. CIP2A has been shown to regulate phosphorylation and activity of numerous oncoproteins, promoting malignant cell growth and tumorigenesis in various human cancers. High expression levels of CIP2A have been observed in multiple cancer types, such as head and neck cancer, colon cancer, gastric cancer, breast cancer, prostate cancer, and lung cancer, correlating with poor patient prognosis and disease aggressivity. Additionally, CIP2A is implicated in resistance to cancer treatments, such as imatinib in chronic myeloid leukemia.

Protein CIP2A also known as cancerous inhibitor of PP2A (CIP2A) is a protein that in humans is encoded by the KIAA1524 gene. CIP2A is a regulatory protein involved in the inhibition of the serine-threonine phosphatase activity of Protein phosphatase 2A (PP2A). PP2A is a trimeric enzyme composed of a catalytic C-subunit, a scaffolding A-subunit, and various regulatory B-subunits, which collectively dephosphorylate a vast majority of cellular serine/threonine phosphorylated proteins, including many involved in cancer progression. CIP2A has been shown to regulate phosphorylation and activity of numerous oncoproteins, promoting malignant cell growth and tumorigenesis in various human cancers. High expression levels of CIP2A have been observed in multiple cancer types, such as head and neck cancer, colon cancer, gastric cancer, breast cancer, prostate cancer, and lung cancer, correlating with poor patient prognosis and disease aggressivity. Additionally, CIP2A is implicated in resistance to cancer treatments, such as imatinib in chronic myeloid leukemia.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1368740269 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot cip2a-2359119-5fe37fc708c5e37e · hash 5fe37fc708c5e37e5e2ce70676ffc73284ea0423c096f40b302e2c383c288e2d · captured 1786387367.0 · version history

Cite this page as: encyclopegia.org, “Cip2a”, snapshot cip2a-2359119-5fe37fc708c5e37e. https://encyclopegia.org/a/cip2a

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.